Rocket Pharmaceuticals adds RP-A601 for PKP2-ACM to cardiac gene therapy pipeline
Jan. 10, 2023
Rocket Pharmaceuticals Inc. has added RP-A601 to its cardiac gene therapy portfolio for the treatment of arrhythmogenic cardiomyopathy due to plakophilin 2 pathogenic variants (PKP2-ACM).
